Convelo’s Mission:
Pioneering MS Breakthroughs for Enhanced Quality of Life
At Convelo Therapeutics, we’re deeply committed to the challenge of tackling neurodegenerative diseases, especially multiple sclerosis (MS), which affects nearly a million people in the U.S.
In MS, the patient’s immune system attacks the myelin sheath of the central nervous system. This attack leads to severe nerve damage. Despite over 15 approved treatments focusing on immune response, patients continue to experience nerve damage and a progression towards disability.
We feel this gap in treatment represents an opportunity for profound change – myelin regeneration and thus treatment of MS.
Embarking on the
Journey of Remyelination
In the central nervous system, the myelin sheath is crucial. It’s created by a specialized cell known as an oligodendrocyte. This sheath does two important things. It allows neurons to communicate quickly and efficiently. It also protects the neurons and their processes from damage.
Oligodendrocytes are unique. They are among the few cells in the central nervous system that renew themselves. They continuously produce and thicken the myelin. This happens in response to the need for plasticity and repair.
However, challenges arise with certain neurological traumas and diseases, such as MS. In these cases, the myelin sheath can be damaged or lost. This leaves neurons, which do not renew, exposed to harmful environments.
Fortunately, there's a process for regeneration. Myelin regeneration is carried out by oligodendrocyte progenitor cells. These cells are a type of abundant stem cell in the central nervous system. They are the main source of new myelin.
At Convelo, our main objective is to improve this regeneration process. We aim to enhance remyelination by promoting the differentiation of these progenitor cells. We want them to mature into oligodendrocytes that can create myelin.
By focusing on directly stimulating repair, we hope to achieve significant results. Our goal is not just to slow the progression of disability. We aim to reverse it.
Innovative
Drug Discovery Platform
Our journey began with multiple pivotal discoveries
Our unique cell-based screening platform enables us to rapidly identify potential new treatments for MS and other demyelinating disorders. With our advanced lab facilities, we can expedite the journey from discovery to clinical trials.
Bench to Bedside,
Evidence Based Therapies.
Since our inception in 2017, Convelo Therapeutics has continued to grow and understand the complexities of drug discovery for multiple sclerosis. Integrating state of the art scientific-machinery, automated neural-network based analysis and leading medicinal chemistry, our research and development team has identified multiple drug-like potential therapeutics which accelerate remyelination.
Building a Robust Pipeline.
Convelo has identified multiple chemically distinct drug-candidates for progression targeting two distinct enzymes that drive oligodendrocyte regeneration
Investing in
A Promising Future
With a strong financial foundation, backed by an initial $7.8 million financing, $12.2 million follow-on financing, along with a comprehensive worldwide license agreement with Case Western Reserve University, we’re propelling our drug pipeline towards clinical trials. Our preclinical studies in MS mouse models and human brain organoids are showing promising results in myelin production.
Convelo Therapeutics
stands at the forefront of scientific rigor, innovative thinking, and a deeply mission-driven approach. Together with our partners and dedicated team, we’re forging a future filled with hope and groundbreaking treatments for MS patients.
